Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT05253482 |
Other study ID # |
WCT 7 |
Secondary ID |
|
Status |
Completed |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
January 5, 2022 |
Est. completion date |
July 30, 2023 |
Study information
Verified date |
October 2023 |
Source |
Karabuk University |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Background and purpose: Although wet cupping therapy (WCT) is in use, clinical investigations
of its efficiency are scarce. The aim of this study was to evaluate the effects of wet
cupping therapy (WCT) on fibromyalgia syndrome Methods: The patients will be randomized into
two groups. WCT will be applied once a month to patients in the intervention group while the
control group will be on standard therapy for fibromyalgia. An evaluation will be made before
treatment and at the 3rd month using the Fibromyalgia Impact Survey (FEA), VAS, and
EuroQol-5D (EQ-5D-3L) quality of life scale.
Description:
Background: Cupping therapy is a traditional treatment method especially belonging to our
geography. In addition to being on the agenda as a traditional treatment method all over the
world in recent years, it has also been the subject of an increasing number of scientific
studies in the medical literature. In addition to studies investigating positive effects on
blood biochemistry such as reducing LDL and TGS levels (1,2), removing heavy metals from the
blood (3), there are also studies showing that it is effective in the treatment of migraine
(4) and in the treatment of nonspecific low back pain (5). As a result of clinical studies,
it was determined that cupping is effective in painful conditions (headache, myofascial pain,
fibromyalgia), calcification, gonorrhea, spondylosis.
It has also been found to be effective in skin diseases (such as acne, herpes zoster),
vascular diseases, blood pressure problems, lung and respiratory diseases, and some
psychiatric disorders (as a tranquilizer in depression, schizophrenia)(6,7,8,9,10,11, 12,13).
It has been suggested that wet cupping therapy stimulates healing by removing inflammatory
mediators and toxins from the body. Some practitioners claim that it reduces or even seizes
pain by regulating the autonomic nervous system. (13).
Purpose: The aim of our study is to investigate how and to what extent wet cupping therapy
will affect the patients diagnosed with fibromyalgia.
Method: The patients who were referred to Umraniye Training Hospital Physical Therapy and
Rehabilitation Polyclinic will be enrolled in the study.
The inclusion criteria are being 18-65 years old, having been diagnosed with fibromyalgia
(ACR 2016 diagnosis criteria), and consenting to participate in the study. Those who are
accompanied with any chronic disease and on daily medication, contraindicated to WCT as
determined in the routine blood tests that were routinely performed before the prior to
application (Hgb <9,5; INR> 1,2,; Hgb <9,5, etc) and who received WCT in the last three
months will be excluded.
The volunteers will be randomized into two separate groups as study and control group Control
group will not receive any intervention while the study group will undergo 3 successive WCT
sessions once in a month throughout 3 months (On 0, 30, and 60 days). Vacuum cups will used
on different acupuncture points to perform WCT: The one on the posterior median line, in the
depression below the processus spinosus of the 7th cervical vertebra, was DU 14 (Dazhui)
point; the ones on the back, 3.0 cm lateral to the lower border of the spinous process of the
3rd thoracic vertebra interscapulum region were UB 42 (Pohu) bilateral points; and the ones
on the back, 3.0 cm lateral to the lower border of the spinous process of the 7th thoracic
vertebra were UB 46 (Geguan) bilateral points and additionally the patient's trigger points
which we detect during the examination. There will be 5-7 points in total. The technique used
will be triple S (Sucking, Scarification, Sucking) in all sessions.
At 0 and 3 months, to both patient groups those questionnaires: Fibromyalgia Impact Survey
(FEA), VAS, and EuroQol-5D (EQ-5D-3L) quality of life scale will be applied. Evaluation will
be made between two groups regarding the scores of those scales